Caris Life Sciences (CAI) Liabilities and Shareholders Equity (2024 - 2026)

Caris Life Sciences has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $1.2 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 28.75% year-over-year to $1.2 billion in Q2 2026; TTM through Jun 2026 was $4.5 billion, a 246.65% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 227.48% from the prior year.
• Liabilities and Shareholders Equity was $1.2 billion for Q2 2026 at Caris Life Sciences, up from $1.2 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.2 billion in Q2 2026, with the low at $343.7 million in Q4 2024.
• Average Liabilities and Shareholders Equity over 3 years is $966.8 million, with a median of $1.1 billion recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity soared 227.48% in 2025, then grew 28.75% in 2026.
• Over 3 years, Liabilities and Shareholders Equity stood at $343.7 million in 2024, then jumped by 227.48% to $1.1 billion in 2025, then rose by 9.24% to $1.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.2 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.